Agilent Technologies (NYSE:A) updated its FY19 earnings guidance on Tuesday. The company provided EPS guidance of $3.03-3.07 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.07. The company issued revenue guidance of $5.09-5.13 billion, compared to the consensus revenue estimate of $5.19 billion.Agilent Technologies also updated its FY 2019 guidance to $3.03-3.07 EPS.
A number of brokerages recently commented on A. UBS Group assumed coverage on Agilent Technologies in a research report on Friday, March 15th. They issued a buy rating and a $92.00 price target on the stock. Cowen raised their price objective on Agilent Technologies from $80.00 to $90.00 and gave the company an outperform rating in a research note on Tuesday, March 26th. Deutsche Bank reaffirmed a buy rating and issued a $90.00 price objective on shares of Agilent Technologies in a research note on Thursday, February 21st. Robert W. Baird reaffirmed a buy rating and issued a $82.00 price objective (up from $77.00) on shares of Agilent Technologies in a research note on Wednesday, February 20th. Finally, Barclays raised their price objective on Agilent Technologies from $80.00 to $83.00 and gave the company an overweight rating in a research note on Thursday, February 21st. Two investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Agilent Technologies currently has a consensus rating of Buy and a consensus target price of $87.17.
Shares of A stock traded up $2.17 during mid-day trading on Tuesday, reaching $76.01. 2,273,568 shares of the stock traded hands, compared to its average volume of 1,895,391. Agilent Technologies has a 1-year low of $60.42 and a 1-year high of $82.27. The firm has a market capitalization of $24.48 billion, a price-to-earnings ratio of 27.24, a PEG ratio of 2.14 and a beta of 1.33. The company has a current ratio of 3.39, a quick ratio of 2.79 and a debt-to-equity ratio of 0.36.
Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Tuesday, May 14th. The medical research company reported $0.71 EPS for the quarter, missing the Zacks’ consensus estimate of $0.72 by ($0.01). Agilent Technologies had a net margin of 22.86% and a return on equity of 19.90%. The firm had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same period in the previous year, the business posted $0.65 earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. On average, sell-side analysts predict that Agilent Technologies will post 3.06 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd were given a dividend of $0.164 per share. The ex-dividend date was Monday, April 1st. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.86%. Agilent Technologies’s dividend payout ratio (DPR) is 23.66%.
In other news, CEO Michael R. Mcmullen sold 8,746 shares of the firm’s stock in a transaction dated Friday, February 15th. The stock was sold at an average price of $77.67, for a total transaction of $679,301.82. Following the completion of the transaction, the chief executive officer now directly owns 447,684 shares in the company, valued at $34,771,616.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Rodney Gonsalves sold 6,155 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $79.79, for a total value of $491,107.45. The disclosure for this sale can be found here. Insiders have sold 57,329 shares of company stock valued at $4,535,225 over the last 90 days.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates through three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software and information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps; and measurement technologies.
Further Reading: Why is the ROA ratio important?
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.